Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Combining a GLP-1 receptor agonist plus insulin proves more effective than other diabetes therapies

A new study supports the use of GLP-1 agonists in combination with basal insulin in the management of patients with type 2 diabetes.

Patient measures his blood sugar levels with a blood glucose meter

Source: Ververidis Vasilis /

The meta-analysis included 15 studies that compared GLP-1 agonist and basal insulin combination therapy with other antidiabetic drugs in 4348 adults with type 2 diabetes

“A powerful and safer alternative to insulin” achieved robust glucose control for diabetes with no increased risk of hypoglycaemia or weight gain, conclude the authors of a systematic review of therapies published in The Lancet[1].

The combination of a glucagon-like peptide-1 receptor (GLP-1) agonist plus basal insulin offered the “ideal triumvirate”, according to Laura Young and John Buse from the University of North Carolina, USA, in an accompanying commentary to the meta-analysis[2].

The systematic review included 15 studies that compared GLP-1 agonist and basal insulin combination therapy with other antidiabetic drugs in 4,348 adults with type 2 diabetes.

The researchers, led by Ravi Retnakaran, from Mount Sinai Hospital, Toronto, Canada, noted that the high cost of both GLP-1 agonists and insulin analogues is likely to be the major barrier to widespread adoption of the treatment.

Combination therapy reduced glycated haemoglobin (HbA1c) by a mean of 0.44% more than other therapies and significantly improved the likelihood of achieving an HbA1c of 7.0% or lower, with a relative risk (RR) of 1.92. Furthermore, combination therapy was associated with a mean 3.22 kg reduction in body weight and did not increase the risk of hypoglycaemia (RR 0.99) versus other therapies.

Compared with full basal-bolus insulin regimens, the combination of GLP-1 agonist plus insulin resulted in a marginal 0.1% reduction in HbA1c, a 33% lower risk of hypoglycaemia and a mean 5.66-kg reduction in weight.

Retnakaran and colleagues say their data indicate that combining a GLP-1 agonist with basal insulin “can achieve the ideal triumvirate of short-term outcomes in diabetes management: potent glucose-lowering capacity without increased hypoglycaemia or weight gain”.

“Our findings clearly lend support to the use of GLP-1 agonists in combination with basal insulin in the clinical management of patients with type 2 diabetes.”

Victoria Ruszala, a diabetes pharmacist at North Bristol NHS Trust, said that the study provided reassurance about the co-prescription of GLP-1 agonists and basal insulin, already widely practised and endorsed by expert bodies such as the Association of British Clinical Diabetologists.

Ruszala added that while the meta-analysis summarised the overall benefits of combination therapy, there are likely to be differences in the efficacy and side-effects associated with individual GLP-1 agonists.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066519

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.